drugset / Trial / NCT03430791
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Phase 2
Terminated
5 enrolled
Baptist Health South Florida
Bristol-Myers Squibb · collabNovoCure Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.
Timeline
- Start
- 2018-12-05
- Primary completion
- 2020-05-29
- Completion
- 2021-01-27
Outcome
Outcome not reported
Stopped (Enrollment): “Study Investigator/Sponsor decided to end enrollment earlier.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |